Arete Therapeutics Lands $16.7M

Wednesday, November 19, 2008

Arete Therapeutics Lands $16.7M

Hayward-based Arete Therapeutics, which is a biotechnology firm focused on soluble epoxide hydrolase (s-EH) inhibitors, has added $16.7M in a Series A tranche financing. According to Arete, the tranche was led by Frazier Healthcare Ventures and Alta Partners, and also includes prior investors Burrill & Company, Three Arch Partners, and Altitude Life Science Ventures. The round brings the company's Series A to over $51M. The firm said it will use the funding to move towards a Phase II clinical trial in Q1 o 2009. The firm's compounds are being targeted at treating metabolic, inflammatory and cardiovascular disease.
posted on Wednesday, November 19, 2008 (Link to more information)

RSS subscri
be via email Email Twitter

Previous Issues

Thursday, July 2, 2009
Wednesday, July 1, 2009
Tuesday, June 30, 2009
Monday, June 29, 2009
Friday, June 26, 2009